Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Providers Satisfied with Carriers/MACs
Roberta Buell, MBA, Sausalito Healthcare Partners
Cancer Science: Mutations in the ALK Receptor Kinase cause Neuroblastoma
Sara Hartley, MDLinx Oncology
Technology Advances: Laser Microscopy Offers Vista of Real-Time Cell Movements
Dorothy J. Schirf, MD, MDLinx Oncology
  See all
metastatic renal cell carcinoma;PAX-2,RCC antigen, and antiphosphorylated H2AX sntibody Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody ([gamma]-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration
Diagnostic Cytopathology, 07/21/08
Print     Email This Article     Save in My Library   Free Abstract
Wasco MJ et al. – Both PAX-2 and -H2AX are sensitive markers for diagnosis of metastatic renal cell carcinoma (RCC), with improved ease of interpretation compared with RCC-Ma; combination of all 3 markers identified 87% of cases; failure to stain for both PAX-2 and -H2AX suggests against, but does not disprove, RCC diagnosis

Methods

  • Study of use of two new immunostains, PAX-2 and -H2AX, in FNA material for diagnosis of metastatic RCC and in comparison with RCC-Ma
  • Identification of 29 cases of metastatic RCC and TMA of an additional 30 RCC cases

Results
  • RCC-Ma in a membranous pattern of staining identified 15/27 (56%) metastatic RCC; interpretation complicated by focality of staining and non-specific cytoplasmic staining
  • PAX-2 stained 23/29 (79%) of tumors in a nuclear stain, most strongly
  • Gamma-H2AX stained 19/26 (73%) of metastatic RCC strongly in a nuclear stain
  • In the TMA, strong, diffuse nuclear staining with -H2AX present in 22/30 RCC (73%)
  • With weak staining included as positive, 26/30 (87%) were positive
  • PAX-2 stained RCC TMA with a lower percentage at 56%, including weaker staining intensity
  • Both PAX-2 and -H2AX showed patchy staining of normal renal tubules

 

--- BASIC SCIENCE/GENETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

--- DIAGNOSTICS/RADIOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- RENAL/UROLOGIC TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.